AIP
NKTR icon

Arrowpoint Investment Partners’s Nektar Therapeutics NKTR Stock Holding History

Arrowpoint Investment Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Sell
2,830
-2,097
-43% -$119K 0.18% 69
2025
Q4 		$208K Buy
+4,927
New +$276K 0.03% 99

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Arrowpoint Investment Partners's NKTR Position: Q1 2026 in Review

Arrowpoint Investment Partners reduced its Nektar Therapeutics (NKTR) stake by 43% in Q1 2026, selling an estimated $119K and leaving 2,830 shares worth $204K. The position accounts for 0.18% of the portfolio, ranked #69.

Arrowpoint Investment Partners first reported a position in NKTR in Q4 2025 and has held it in 2 quarters since. The position peaked at $208K in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Arrowpoint Investment Partners held 2,830 shares of Nektar Therapeutics worth $204K as of Q1 2026.
  • Arrowpoint Investment Partners sold 2,097 Nektar Therapeutics shares in Q1 2026, an estimated $119K.
  • Nektar Therapeutics made up 0.18% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #69 holding.
  • Arrowpoint Investment Partners first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Arrowpoint Investment Partners's Nektar Therapeutics position peaked at $208K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.